Oxymatrine
| Names | |
|---|---|
| IUPAC name
1λ5-Matridine-1,15-dione | |
| Systematic IUPAC name
(41S,7aS,13aR,13bR)-Dodecahydro-1H,10H-4λ5-dipyrido[2,1-f:3′,2′,1′-ij][1,6]naphthyridine-4,10(5H)-dione | |
| Other names
Matrine oxide, matrine N-oxide, matrine 1-oxide | |
| Identifiers | |
3D model (JSmol) |
|
| ChemSpider | |
| ECHA InfoCard | 100.106.342 |
PubChem CID |
|
| UNII | |
CompTox Dashboard (EPA) |
|
| |
| Properties | |
| C15H24N2O2 | |
| Molar mass | 264.369 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references | |
Oxymatrine (matrine oxide, matrine N-oxide, matrine 1-oxide) is one of many quinolizidine alkaloid compounds extracted from the root of Sophora flavescens, a Chinese herb. It is very similar in structure to matrine, which has one less oxygen atom. Oxymatrine has a variety of effects in vitro and in animal models, including protection against apoptosis, tumor and fibrotic tissue development, and inflammation. Furthermore, oxymatrine has been shown to decrease cardiac ischemia (decreased blood perfusion), myocardial injury, arrhythmias (irregular heartbeats), and improve heart failure by increasing cardiac function.